Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Total Current Liabilities
All obligations due within one year.
Equillium, Inc.NASDAQ: EQ
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 44.3% from a year ago
Total current liabilities stood at $3.35M at the end of Q1 FY2026, down 44.3% from a year earlier and up 14.0% from the prior quarter. Over 3 fiscal years it compounded at -54.9% a year.
Context
- Total current liabilities amounted to 5.3% of total assets at the end of Q1 FY2026, down 30.6 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -44.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.93M USD
- Year-over-year change
- -53.8%
- 4-year CAGR
- -24.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.93M | -53.8% |
| FY2024 | 2024-12-31 | 6.36M | -76.9% |
| FY2023 | 2023-12-31 | 27.57M | -13.9% |
| FY2022 | 2022-12-31 | 32.04M | +259.4% |
| FY2021 | 2021-12-31 | 8.92M | — |
Total Current Liabilities vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's Mar 2026 total current liabilities of $3.35M is the 8th highest of the 10 companies compared; the peer median is $13.57M.
- Its year-over-year change of -44.3% is the 8th highest of 10, against a peer median of -6.5%.
- Total current liabilities amounts to 5.3% of total assets for EQ, versus a peer median of 23.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $103.39M | +40.3% | -27.0% | 29.0% | |
| Mar 2026 | $38.88M | +56.6% | +32.4% | 177.6% | |
| Mar 2026 | $25.18M | -23.1% | +22.4% | 211.5% | |
OSTXOS Therapies Incorporated | Mar 2026 | $16.95M | +379.4% | +24.2% | 232.3% |
| Mar 2026 | $13.57M | -6.5% | -12.1% | 4.2% | |
| Mar 2026 | $11.78M | -24.8% | -6.8% | 21.0% | |
| Mar 2026 | $7.39M | -52.3% | +5.3% | 23.9% | |
| Mar 2026 | $3.35M | -44.3% | -54.9% | 5.3% | |
| Mar 2026 | $1.82M | -67.8% | -6.6% | 9.2% | |
| Mar 2026 | $827.31K | +26.8% | +13.1% | 14.3% | |
| Peer median (excluding EQ) | $13.57M | -6.5% | +5.3% | 23.9% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M |
| Short-term Investments | 30.35M | 11.92M | 17.65M | 4.49M | 0 |
| Net Receivables | 0 | 4.11M | 6.29M | 1.14M | 108K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8K | 235K | 429K | (547K) |
| Total Current Assets | 83.37M | 76.74M | 49.35M | 24.98M | 30.28M |
| Property, Plant & Equipment (Net) | 1.88M | 1.58M | 1.11M | 626K | 658K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 153K | 104K | 70K | 0 | 0 |
| Total Non-current Assets | 2.04M | 1.69M | 1.18M | 626K | 658K |
| Total Assets | 85.41M | 78.42M | 50.53M | 25.6M | 31.89M |
| Account Payables | 1.23M | 3.98M | 4.71M | 2.68M | 755K |
| Short-term Debt | 1.43M | 5.71M | 0 | 197K | 363K |
| Tax Payables | 0 | 0 | 0 | 365K | 0 |
| Deferred Revenue | 0 | 14.7M | 15.73M | 0 | 0 |
| Other Current Liabilities | 3.38M | 0 | 3.64M | 2.68M | 1.82M |
| Total Current Liabilities | 8.92M | 32.04M | 27.57M | 6.36M | 2.93M |
| Long-term Debt | 8.75M | 3.24M | 0 | 0 | 356K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 10.38M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.99M | 14.44M | 384K | 187K | 356K |
| Total Liabilities | 18.9M | 46.48M | 27.96M | 6.54M | 3.29M |
| Common Stock | 2K | 3K | 3K | 3K | 5K |
| Retained Earnings | (109.98M) | (172.41M) | (185.74M) | (193.81M) | (216.21M) |
| Accumulated OCI | (138K) | 76K | 140K | 781K | 363K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 66.51M | 31.94M | 22.57M | 19.06M | 28.6M |
| Total Debt | 11.79M | 10.19M | 824K | 384K | 719K |
| Net Debt | (38.58M) | (48.92M) | (22.39M) | (17.7M) | (29.56M) |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.